Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.

ABSTRACT:

Background

Aspirin desensitization followed by daily aspirin use is an effective treatment for aspirin-exacerbated respiratory disease (AERD).

Objective

To assess clinical features as well as genetic, immune, cytological and biochemical biomarkers that might predict a positive response to high-dose aspirin therapy in AERD.

Methods

We enrolled 34 AERD patients with severe asthma who underwent aspirin desensitization followed by 52-week aspirin treatment (650 mg/d). At baseline and at 52 weeks, clinical assessment was performed; phenotypes based on induced sputum cells were identified; eicosanoid, cytokine and chemokine levels in induced sputum supernatant were determined; and induced sputum expression of 94 genes was assessed. Responders to high-dose aspirin were defin

SUBMITTER: Tyrak KE 

PROVIDER: S-EPMC9292205 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature